Dublin, July 31, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/d6g555/global) has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering.
Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported.
Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by MOA
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
17. Key Late-Stage Pipeline Candidates
18. Other Prominent Vendors
19. Key Vendor Analysis
20. Other Reports in this Series
Companies Mentioned:
- Boehringer Ingelheim GmbH
- GlaxoSmithKline plc
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Abbvie Inc.
- Akorn Inc.
- Astellas Pharma Inc.
- Desitin Arzneimittel GmbH
- Endo International plc
- F. Hoffmann-La Roche Ltd.
- H. Lundbeck A/S
- Kyowa Hakko Kirin
- Merck & Co. Inc.
- Orion Corp.
- STADA Arzneimittel AG
- UCB Inc.
- US WorldMeds LLC
- Valeant Pharmaceuticals International Inc.
For more information visit http://www.researchandmarkets.com/research/d6g555/global